{"entity":{"id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of EGL-001 in advanced solid tumours, run by Egle Therapeutics, now recruiting.","summary":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06622486 by Egle Therapeutics, with 50 participants planned, started 2024-09-27 and due to reach its primary completion in 2027-01-23. Interventions recorded: EGL-001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06622486","url":"https://clinicaltrials.gov/study/NCT06622486"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06622486","phase":"1/2","setting":"First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced And/or Metastatic Solid Tumors","sponsor":"Egle Therapeutics","participation":[{"nct":"NCT06622486","source":"https://clinicaltrials.gov/study/NCT06622486","fetchedAt":"2026-10-07T16:54:51.841Z","studySha256":"d3ad59ff796e9a7e2d2d72b7791eb878d992a74d487ff8b02515ff21671127df","overallStatus":"RECRUITING","lastUpdatePosted":"2024-11-07","leadSponsor":"Egle Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":50,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":3,"countries":["France","Spain"]}],"started":"2024-09-27","startedType":"actual","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06622486/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}